Durolane SJ for Treatment of Rhizarthrosis

Not Applicable

Completed

Brief Summary: The main objective of the trial is to assess the clinical changes in terms of physical examination, VAS Scale and the Quick-DASH questionnaire, and the biomechanical parameters in terms of mobility of the TMC joint, the grip strength of the hand and lateral pinch strength in patients with rhizarthrosis after administration of viscosupplementation.

The secondary objectives of the trial will be to assess the safety of the treatment with viscosupplementation, and the correlation between the clinical and biomechanical changes at the end of the trial.

Detailed Description: This is a prospective, open, non-comparative study in 36 subjects with rhizarthrosis, comparing signs and symptoms before and after a single injection of DUROLANE SJ in the affected hand.

Subjects were assessed pre-treatment and at 1, 3, and 6 months post-treatment. This study is associated with a post marketing commitment with the European Notified Body, BSI, to confirm DUROLANE SJ's effectiveness in rhizarthrosis.

Recruitment & Eligibility

Inclusion Criteria

Subjects of both sexes aged 18 to 75 years.
Diagnosis of Grade II-III rhizarthrosis in either hand, according to the criteria of Eaton and Littler.
TMC joint pain lasting longer than 6 months and baseline pain value greater than or equal to 4 on the VAS scale (0 to 10) and less than 4 in the contralateral hand joint if there is pain.

Exclusion Criteria

Anticoagulant medication
Rheumatic disease involving the wrist, hand and fingers, such as rheumatoid arthritis or gout
Active rheumatoid arthritis
Previous surgery of the hand
Systemic infectious processes
Neoplastic disease
Subjects with contraindications to hyaluronic acid
Subjects with known hypersensitivity to hyaluronic acid or any of the components of the preparation under study
Previous hyaluronic acid injections in the hand
Subjects likely to miss the clinical follow-up visits
Taking of analgesics 24 hours before scheduled clinical assessments
Pregnant subjects
Any condition that in the opinion of the physician recommends exclusion of the subject

Arm && Interventions

Group	Intervention	Description
Durolane SJ	Durolane SJ	single dose injection. One infiltration of the study product in the trapeziometacarpal (TMC) joint. The study treatment contains sodium hyaluronate 20 mg/mL, in a 1 mL prefilled syringe.

Primary Outcome Measures

Name	Time	Method
Change From Baseline in Pain Measured by the VAS Scale	Baseline and 26 weeks	Visual Analogue Scale (VAS) pain in injected hand. The VAS scale ranges from 0 cm (least pain) to 10 cm (most pain). A Visual Analogue Scale (VAS) is a measurement instrument that measures a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Biomechanical Function, Measured by the Quick DASH Questionnaire	Baseline and 26 weeks	The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a 30-item questionnaire that looks at the ability of a patient to perform certain upper extremity activities.This is a self-report questionnaire that patients can use to rate difficulty and interference with daily life. Quick DASH questionnaire is a shortened version of the DASH Outcome Measure which uses 11 items to measure physical function and symptoms in people with musculoskeletal disorders of the upper limb. Possible scores range from 11-55, which can be remapped to a 0-100 scale. This latter ranges from 0 units (most functionality) to 100 units (least functionality).

Locations (3): Hospital Universitari Vall d'Hebron
🇪🇸
Barcelona, Spain
Corporació Sanitària Parc Taulí
🇪🇸
Barcelona, Spain
Hospital Sant Joan Despi Moises Broggi
🇪🇸
Sant Joan Despí, Barcelona, Spain